title: Design, synthesis and biological evaluation of new thalidomide analogues as TNF-α and IL-6 production inhibitors.
abstract: Several thalidomide analogues were synthesized and compared to thalidomide and its more active analogue, lenalidomide, for their ability to inhibit the production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-α and interleukin (IL)-6 by LPS-activated peripheral blood mononuclear cells (PBMCs). Among these compounds, two analogues containing sulfonyl group displayed interesting downregulation of TNF-α and IL-6 production.
authors.affiliation: UMR CNRS 6239 GICC Génétique-Immunothérapie-Chimie et Cancer, Equipe 5, Laboratoire de Chimie Organique et Thérapeutique, Université de Tours François Rabelais, France.
authors.forename: Charlotte
authors.initials: C
authors.lastname: Chaulet
authors.forename: Cécile
authors.initials: C
authors.lastname: Croix
authors.forename: David
authors.initials: D
authors.lastname: Alagille
authors.forename: Sylvain
authors.initials: S
authors.lastname: Normand
authors.forename: Adriana
authors.initials: A
authors.lastname: Delwail
authors.forename: Laure
authors.initials: L
authors.lastname: Favot
authors.forename: Jean-Claude
authors.initials: JC
authors.lastname: Lecron
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Viaud-Massuard
mesh_terms: D015536:Down-Regulation; D015195:Drug Design; D006801:Humans; D015850:Interleukin-6 / Q000378:metabolism*; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D013792:Thalidomide